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ABSTRACT: DNA co-condensates were formed by reacting [125I]DNA with an
admixture of a high-mannose glycopeptide (Man9-CWK18) and either of two poly
(ethylene glycol) peptides (PEG-VS-CWK18 or PEG-SS-CWK18) followed by cross-
linking with 6±50 mol equiv of glutaraldehyde. [125I]DNA co-condensates were
administered intravenously in mice to determine the in¯uence of peptide DNA
formulation parameters on speci®c targeting to Kupffer cells. Optimal targeting to
Kupffer cells required the combined use of 50 mol % Man9-CWK18 and PEG-CWK18 to
mediate speci®c recognition by the mannose receptor to Kupffer cells. The cellular
uptake of cross-linked Man9-CWK18/PEG-CWK18 DNA co-condensates was receptor
mediated since Kupffer cell targeting was inhibited by pre-administration of Man-
bovine serum albumin (BSA) but not BSA. An optimized formulation targeted 60% of the
dose to the liver, with 80% of the liver-targeted DNA localized to Kupffer cells. Cross-
linking with either 6, 15, or 50 mol equiv of glutaraldehyde led to a corresponding
decrease in the metabolism rate of DNA in liver as measured by half-live- of 4, 6, and
39 h, respectively. Tail vein dosing of 50 mg of DNA co-condensates cross-linked with
6 mol equiv of glutaraldehyde produced detectable levels of human a1-antitrypsin in
blood after 12 h, which peaked at day six and persisted for 10 days. The level of human
a1-antitrypsin was elevated two-fold each day when dosing with DNA co-condensates
cross-linked with 15 mol equiv of glutaraldehyde, revealing a correlation between the
metabolic stability of the DNA in liver and level of gene expression. In addition to
possessing greater metabolic stability, DNA co-condensates cross-linked with 50 mol
equiv of glutaraldehyde, but lacking a targeting ligand, avoided rapid liver uptake and
possessed a prolonged pharmacokinetic half-life, providing insight into a means to
target DNA condensates to peripheral tissues. ß 2001 Wiley-Liss, Inc. and the American
Pharmaceutical Association J Pharm Sci 90:2010±2022, 2001
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INTRODUCTION
Polylysine has been derivatized with galactose, N-
glycans, or glycoproteins to prepare carriers used
to form DNA condensates that target the asialo-
glycoprotein receptor (ASGP-R) on hepatocytes
and mediate transient gene expression in vivo.1±4
Although low levels of transient gene expression
have been achieved in animals using these ®rst-
generation delivery carriers, both the level and
duration of gene expression need to be signi®-
cantly improved before intravenously dosed tar-
geted nonviral gene delivery systems will have
clinical utility.5
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A plausible strategy to increase the level and
duration of gene expression would be to block the
metabolism rate of DNA delivered to tissues. In
support of this proposal, one report found that the
metabolic stability of asialoorosomucoid poly-
lysine DNA condensates delivered to hepatocytes
was extended from 1 to 7 days by performing a
partial hepatectomy to increase the residence
time of DNA in regenerating hepatocytes.6
Another study found that the metabolic rate of
DNA in liver was decreased by substituting poly-
D-lysine for poly-L-lysine as a DNA carrier,
illustrating that proteolysis plays a key step in
the residence time of DNA in the target cell.7 A
related report found that the duration of gene
expression in vivo was related with the length of
poly-L-lysine.8
In addition to the ASGP-R, the mannose
receptor on Kupffer cells has been used as a
model system to study transient gene expression
in vivo. Ferkol et al.9 used mannosylated
polylysine to form DNA condensates that tar-
geted liver and spleen, mediating maximal luci-
ferase expression at day 4 in spleen. In a
subsequent paper, Ferkol et al.10 found that
mannosylated polylysine DNA condensates tar-
geted lung macrophages in rat and expressed
detectable levels of human a1-antitrypsin (hAAT)
at day 4. Nishikawa et al.11 reported that man-
nosylated polylysine DNA condensates avoided
entrapment in the lung and determined expres-
sion of chloramphenicol transferase in liver at
48 h.
No prior studies have attempted to optimize
carrier molecules to maximally protect DNA from
metabolism and demonstrate how this in¯uences
the level or duration of gene expression. Low mole-
cular weight (LMW, 20 amino acids or less)
peptides have been proposed as replacements for
high molecular weight (HMW) polylysine to allow
systematic optimization of the gene delivery
carrier.12±14 HMW polylysine can only be ran-
domly derivatized, making it dif®cult to control
the location and stoichiometry of poly(ethylene
glycol)(PEG) or carbohydrate attached to the car-
rier molecule.15,16 LMW peptides offer the advan-
tages of being chemically de®ned and can be
selectively derivatized with PEG or carbohydrate
ligands.17,18 The stoichiometry of ligand may be
controlled by forming DNA co-condensates
from admixtures of LMW carriers possessing an
identical peptide.17,18 A signi®cant distinction
between HMW and LMW peptide DNA con-
densates is the requirement of the latter to
be stabilized by cross-linking to insure their
survival during circulation and in the target
tissue.17
In the present study, LMW glycopeptide/PEG-
peptide DNA co-condensates were formed and
stabilized by glutaraldehyde cross-linking for the
purpose of targeting Kupffer cells via the man-
nose receptor. Increasing the degree of cross-
linking on DNA co-condensates revealed a rela-
tionship between the rate of DNA metabolism
and the level of transient gene expression in vivo.
In addition, the results demonstrate that highly
stabilized DNA formulations circulate with a
prolonged pharmacokinetic half-life. Control-
ling these parameters is fundamental to incre-
asing the ef®cacy of nonviral gene delivery
systems.
MATERIALS AND METHODS
Sodium125-I was purchased from Dupont NEN,
Boston, MA. Heparin, D-mannitol, thallium
trichloride, sodium sul®te, potassium iodine,
mannosylated bovine serum albumin (Man-BSA)
bovine serum albumin (BSA), Hepes, collagenase
from clostridium histolyticum type IV, carbonyl
iron, 70% glutaraldehyde, 2,20-azion-bis(3-ethyl-
benzthiaxoline-6-sulfonic acid (ABTS), Tween 20,
antihuman a1-antitrypsin IgG from goat and rab-
bit, and human a1-antitrypsin were purchased
from Sigma, St. Louis, MO. Hydrogen peroxide
(3%) was purchased from Aldrich, Milwaukee, WI.
Agarose was purchased from Gibco-BRL, Gaither-
sburg, MD. Poly(ethylene glycol)-orthopyridyl
disul®de (PEG-OPSS, 5 kDa) was purchased from
Shearwater Inc., Huntswille, AL. Poly(ethylene
glycol)-vinyl sulfone (PEG-VS, 5 kDa) was pur-
chased from Fluka, Ronkonkoma, NY. Ketamine
hydrochloride was purchased from Fort Dodge
Laboratories, Fort Dodge, IA. Xylazine hydro-
chloride was purchased from Miles Inc., Shawnee
Mission, KS. Silastic catheters (0.305 mm inner
diameter 0.635 mm outer diameter) were pur-
chased from Baxter, Obetz, OH. ICR mice (30±
35 g) purchased from Harlan, Indianapolis, IN,
and housed in cages located in a limited access
area with a 12-h light±dark cycle and controlled
temperature (26±288C). Ultrapure 100 DNA puri-
®cation columns were purchased from Qiagen,
Santa Clarita, CA. Analytical and semi-prepara-
tive high-performance liquid chromatography
(HPLC) columns were purchased from Vydac,
Hesperia, CA.
CROSS-LINKED GLYCOPEPTIDE-MEDIATED GENE DELIVERY 2011
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 90, NO. 12, DECEMBER 2001
Radiolabeling Plasmid DNA
Endotoxin-free plasmid DNA encoding hAAT
under transcriptional control of the cytomegalo-
virus promoter (pCMVhAAT)19 was puri®ed from
E. coli with a Qiagen ultrapure column according
to the manufacturer. Plasmid DNA was radiola-
beled with 125I as described previously,20 result-
ing in supercoiled and circular DNA with speci®c
activity ranging from 300 to 450 nCi/mg.
Glycopeptide and PEG-Peptide Synthesis
CWK18 (Cys-Trp-Lys18) was synthesized on a
solid support and puri®ed as previously re-
ported.21 The terminal cysteine was either alky-
lated (AlkCWK18) with iodoacetic acid or used as
an N-glycan or PEG attachment site. A high-
mannose N-glycan was puri®ed from soy bean
agglutinin as the Boc-tyrosinamide derivative
(Man9).22 Man9 was converted to an iodoacety-
lated tyrosinamide oligosaccharide then reacted
with CWK18 to form Man9-CWK18.
17 PEG-VS-
CWK18 and PEG-SS-CWK18 were prepared
as reported previously.18 Man9-CWK18, PEG-
CWK18, and AlkCWK18 stock solutions were quan-
ti®ed by absorbance (e280nm 5600 Mÿ1 cmÿ1
for Trp in PEG-peptides and AlkCWK18,




Man9-CWK18 was combined with either PEG-VS-
CWK18 or PEG-SS-CWK18 to form a 40 nmol/mL
admixture of 2:98, 10:90, or 50:50 mol % Man9-
CWK18/PEG-CWK18 in 5 mM Hepes, 0.27 M
mannitol pH 7.4 (HBM). DNA co-condensates
were formed by combining glycopeptide/PEG-
peptide admixtures with an equal volume of
100 mg/mL pCMVhAAT in HBM while vortexing,
which results in 50 mg/mL DNA co-condensates
prepared at a stoichiometry of 0.4 nmol of peptide
per microgram of DNA or a charge ratio (NH4
/
PO4
ÿ) of 2.4:1. DNA co-condensates formed ins-
tantly but were allowed to equilibrate for 30 min
prior to cross-linking.
Cross-linked DNA co-condensates were formed
by adding 12, 30, or 100 mg of glutaraldehyde to
1 mL of preformed 50 mg/mL DNA co-condensates,
which corresponds to 6, 15, and 50 mol equiv
relative to 1 mol equiv of peptide, followed by
reaction for 12 h at 48C.23 After cross-linking, the
particle size (quasi-elastic light scattering; QELS)
and zeta potential were analyzed on a Zeta-Plus
(Brookhaven Instruments, Co, Holtsville, NY).
Biodistribution and Pharmacokinetic Analysis
of Cross-Linked DNA Co-Condensates
Biodistribution analysis was performed by insert-
ing a single catheter in the right jugular vein of
three anesthetized mice. Cross-linked DNA co-
condensates (2.5 mg of 125I-DNA, 1.0 mCi, in 50 mL
HBM), were dosed iv followed by vein ligation. At
times ranging from 5 to 360 min, mice were
sacri®ced by cervical dislocation, and the major
organs (liver, lung, spleen, stomach, kidney,
heart, large intestine, and small intestine) were
harvested, rinsed with saline, and weighed.
Longer term biodistribution was analyzed by
dosing mice via the tail vein. At 1±3 days, mice
were anesthetized, sacri®ced by cervical disloca-
tion, and dissected as already described. The
radioactivity in each organ was determined by
direct gamma counting and expressed as the tar-
geting ef®ciency, which is de®ned as the percent
of the dose in the target organ.
Pharmacokinetic analysis was performed by
inserting dual jugular vein cannula into anesthe-
tized mice. [125I]DNA formulations were dosed in
the left vein, and 10-mL samples of blood were
taken at 1, 3, 6, 10, 15, 20, 30, 40, 60, 90, 120, and
180 min time points from the right vein followed
by replacement with normal saline. The radio-
activity (cpm) at each time point from triplicate
mice was determined by direct gamma counting.
The data were ®t to a two-compartment model
using PCNONLIN.24
Cellular Distribution of Cross-Linked
DNA Co-Condensates in Liver
Mice were dosed iv in the tail vein with 20 mg of
carbonyl iron in 0.2 mL of saline. After 45 min,
mice were anesthetized, and a single catheter was
inserted into the right jugular vein and used to
dose cross-linked DNA co-condensates (2.5 mg of
[125]DNA, 1 mCi, in 50 mL of HBM). For receptor
blocking experiments, mice were dosed with
3.5 mg of Man-BSA or BSA in 100 mL of saline
1 min prior to dosing DNA formulations. After a
30-min biodistribution, the portal vein was can-
nulated and used to administer 0.2 mL of heparin
(100 U/mL) followed immediately by the perfusion
buffer. The liver was ®rst perfused at 5 mL/min
for 2 min with oxygenated (95% oxygen, 5%
2012 YANG ET AL.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 90, NO. 12, DECEMBER 2001
carbon dioxide) preperfusion buffer (calcium- and
magnesium-free Hepes solution, pH 7.45, 378C),
and then at a rate of 3 mL/min for an additional
3 min. The perfusion was continued for 16±20 min
at 3 mL/min with oxygenated Seglen's Buffer (pH
7.45, 378C) containing 0.058% (w/v) collagenase
type IV. At the start of the perfusion the vena cava
and aorta were cut, and at the completion, the
liver was excised and placed in a Petri dish (48C)
and cut into small pieces. Cells were dislodged
and dispersed in ice-cold Hank's (containing
10 mM Hepes, pH 7.45, 0.1% BSA) and then
incubated at 378C for 20 min with shaking
(30 rpm). The dispersed cells were ®ltered
through a 73-mm mesh ®lter, then transferred to
a 35-mL glass tube. The iron-®lled Kupffer cells
were attracted to the wall of the tube with a
magnet, whereas the other cells were decanted
off. The procedure was repeated three times,
and the Kupffer cells were combined and resus-
pended in 0.8 mL of Hanks Hepes Buffer. The
remaining suspension was centrifuged at 50g for
1 min, and the supernatant was discarded. The
pelleted hepatocytes were washed two times with
ice-cold Hank's±Hepes buffer followed by centri-
fuging at 50g for 1 min. Puri®ed hepatocytes were
resuspended in 2 mL of Hank's±Hepes buffer.
The cell purity (> 90%) and number (6 106
hepatocytes and 4.8 105 Kupffer cells) were
determined with a hemocytometer, and cell
viability (> 90%) was determined by the trypan
blue exclusion test. The radioactive DNA in each
cell fraction was measured by gamma counting.
In Vivo Gene Expression
Mice were dosed iv via the tail vein by infusing
1 mL of 50 mg/mL cross-linked DNA co-conden-
sates over a period of 10 min. Blood was harvested
(1 mL) from 3 mice at 12 h and each day for 10 days
after dosing. The blood was allowed to clot at room
temperature and was centrifuged at 13,000g for
15 min. The serum was stored at ÿ 208C until
assayed by ELISA.
A modi®ed double antibody sandwich ELISA
was used to determine the magnitude of human
alpha-1 antitrypsin (hAAT) gene expression.25
The primary antibody (goat anti-hAAT) was
diluted 1:1000 in 0.1 M sodium bicarbonate
(pH 9.6), added (100 mL) to each well, and incub-
ated overnight at 48C. Nonspeci®c binding was
blocked with 100 mL of 5 w/v % non-fat dry milk in
PBS for 1 h at 378C. Mouse serum samples
(100 mL) or standards were added to each well
and allowed to bind for 2 h at 378C. The secondary
antibody (rabbit anti-hAAT) was diluted 1:1000
in PBS-Tween, added (100 mL) to each well, and
incubated at 378C for 2 h. Anti-rabbit peroxidase
conjugated antibody (100 mL) diluted 1:1000 in
PBS-Tween was added and allowed to bind for 2 h
at room temperature. Finally, substrate solution
(100 mL of 1 mg/mL ABTS in 0.2 M phosphate
buffer, pH 7.6, with 0.003% hydrogen peroxide)
was added and incubated at room temperature for
2 h. After 30 min, the absorbance at 415 nm was
measured on a BioRad 550 microplate reader. The
amount of hAAT expressed was determined by
comparison to a triplicate standard curve of hAAT
prepared in blank mouse serum.
RESULTS
Based on the hypothesis that DNA metabolism is
likely to in¯uence the level and duration of
transient gene expression in vivo, we developed
a formulation that allows systematic control over
this parameter. The three components of the gene
delivery system are (1) a chemically de®ned LMW
glycopeptide and PEG-peptide, (2) a plasmid
encoding hAAT, and (3) a cross-linking agent to
stabilize DNA co-condensates.
LMW carriers were prepared by reacting
the Cys residue on CWK18 with either a single
poly(ethylene glycol) chain to form PEG-VS-
CWK18 or PEG-SS-CWK18 an N-glycan to form
Man9-CWK18, or iodoacetic acid to form
AlkCWK18 (Figure 1). PEG-peptides were used
to block serum protein and cell surface binding by
forming a hydrophilic layer on the surface of DNA
condensates.26 A high-mannose glycopeptide
(Man9-CWK18) was used to mediate targeting to
the mannose receptor found on the surface of
Kupffer cells,27 and AlkCWK18 was substituted
for Man9-CWK18 in control formulations.
Man9-CWK18 (or AlkCWK18)/PEG-peptide ad-
mixtures were used to form DNA co-condensates
according to Scheme 1 in which the admixture
ratio controlled the stoichiometry of peptide con-
jugates bound to DNA.26 In the ®nal step,
glutaraldehyde was used to cross-link DNA co-
condensates by di-Schiffs base formation between
amine groups on neighboring glycopeptides and
PEG-peptides bound to DNA.17
To maximize the targeting of DNA to Kupffer
cells, the admixture ratio of Man9-CWK18 and
PEG-VS-CWK18 was varied while keeping the
glutaraldehyde cross-linking constant at 15
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Figure 1. Structure of Man9-CWK18, PEG-VS-CWK18, PEG-SS-CWK18, and
AlkCWK18. The chemical structure of each LMW DNA condensing peptide used is
illustrated. Each conjugate shares a common 20 amino acid peptide (CWK18) but differs
in the composition of the polymer attached to the cysteine residue.
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equiv. Prior to in vivo analysis, each DNA
formulation was analyzed for particle size and
zeta potential (Table 1). Formulations prepared at
admixture ratios of 2:98, 10:90, and 50:50 mol %
Man9-CWK18/PEG-CWK18 possessed a mean
particle size ranging from 95 to 120 nm and a
surface charge of 3±11 mV (Table 1, C±E).
Substitution of PEG-VS-CWK18 with PEG-SS-
CWK18 did not in¯uence the size or charge of the
DNA co-condensates (Table 1, E versus F).
However, a progressive increase in the mean
particle size occurred for DNA condensates pre-
pared with increasing glutaraldehyde cross-link-
ing (Table 1, E, G±J).
Biodistribution and pharmacokinetic analysis
of cross-linked DNA co-condensates utilized 125I-
labeled plasmid DNA as a tracer to quantitatively
monitor the radioactivity in blood and tissues over
time. Intravenously dosed 125I-plasmid DNA
rapidly, distributes, with 60% of dose recovered
in the liver after 5 min, as reported previously.17
Of the liver targeted DNA, 65% was recovered in
Kupffer cells, with the remaining 35% associated
with hepatocytes (Figure 2A). By comparison, the
nonspeci®c biodistribution of a control formula-
tion composed of cross-linked (15 equiv) 50 mol %
AlkCWK18/PEG-VS-CWK18 DNA co-condensates
revealed 53% targeted to hepatocytes and 47% to
Kupffer cells (Figure 2B). This formulation, which
lacked a targeting ligand but possessed compar-
able particle size and surface charge relative to
experimental formulations (Table 1), was used as
a reference point to determine the in¯uence of
Man9-CWK18 on mediating Kupffer cell target-
ing. Likewise, a second control formulation of
cross-linked (15 equiv) 100 mol % PEG-VS-CWK18
DNA condensates distributed with 41% targeting
hepatocytes and 59% to Kupffer cells.
A signi®cant improvement in selectivity was
afforded when using 2 mol % of Man9-CWK18 and
98 mol % PEG-VS-CWK18, resulting in 61%
recovery in Kupffer cells and 39% in hepatocytes
(Figure 2D). Increasing the ratio of Man9-CWK18
to 10 mol % resulted in an increase in selectivity
with 68% targeting to Kupffer cells and 32% to
hepatocytes (Figure 2E). Likewise, 50 mol Man9-
CWK18 increased the Kupffer cell targeting
selectivity to 80% (Figure 2F), whereas increasing
Man9-CWK18 to 75 mol % failed to further
improve the Kupffer cell targeting selectivity
(Figure 2G). Substituting PEG-SS-CWK18 for
Scheme 1. Preparation of glutaraldehyde cross-
linked DNA co-condensates. DNA co-condensates
formed by reaction of plasmid DNA with an admixture
of PEG-CWK18 and Man9-CWK18 are stabilized with
glutaraldehyde to cross-link residual amino groups.
Both the admixture ratio and glutaraldehyde cross-
linking level are systematically varied to optimize
Kupffer cell targeting and gene expression.








A 116 7 10.2 1.6
B 103 15 1.5 0.5
C 95 10 4.4 0.7
D 109 13 3.4 1.0
E 120 9 11.4 2.2
F 118 6 8.6 3.0
G 101 26 4.6 1.0
H 194 5 3.6 1.4
I 322 24 6.8 2.0
J 383 7 6.4 1.4
aEach formulation was prepared at a DNA concentration of
50 mg/mL, at a stoichiometry of 0.4 nmol of total peptide per
microgram of DNA, and a charge ratio of 2.4:1.
bParticle size is reported as the mean diameter and
standard deviation of three measurements.
cZeta potential is reported as the mean and standard
deviation of 10 measurements: A cross-linked (15 equiv)
AlkCWK18/PEG-VS-CWK18 (50:50); B cross-linked (15 equiv)
PEG-VS-CWK18 (100); C cross linked (15 equiv) Man9-
CWK18/PEG-VS-CWK18 (2:98); D cross-linked (15 equiv)
Man9-CWK18PEG/VS-CWK18 (10:90); E cross-linked
(15 equiv) Man9-CWK18/PEG-VS-CWK18 (50:50); F cross-
linked (15 equiv) Man9-CWK18/PEG-SS-CWK18 (50:50);
G cross-linked (6 equiv) Man9-CWK18/PEG-VS-CWK18
(50:50); H cross-linked (20 equiv) Man9-CWK18/PEG-VS-
CWK18 (50:50); I cross-linked (30 equiv) Man9-CWK18/
PEG-VS-CWK18 (50:50); J cross-linked (50 equiv) Man9-
CWK18/PEG-VS-CWK18 (50:50).
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PEG-VS-CWK18 in 50 mol % Man9-CWK18 DNA
co-condensates also did not in¯uence the Kupffer
cell targeting selectivity (Figure 2H), suggesting
that the disul®de bond linking PEG and CWK18 is
not signi®cantly reduced during circulation.
To support the hypothesis that the Kupffer cell
targeting was mediated by the mannose receptor,
3.5 mg (50 mol excess based on mannose) of
Man-BSA was administered prior to dosing cross-
linked 50 mol % Man9-CWK18/PEG-VS-CWK18
DNA co-condensates. This procedure effectively
blocked reduced cell targeting from 80 to 59%
(Figure 2I), whereas a control experiment, sub-
stituting BSA for Man-BSA failed to reduced
Kupffer cell targeting (Figure 2J).
Comparison of otherwise identical formula-
tions possessing 15 and 50 equiv cross-linking
resulted in 80% targeting to Kupffer cells,
establishing that the level of glutaraldehyde
cross-linking did not alter Kupffer cell targeting
selectivity (Figure 2F versus K). Finally, dose
escalation from 2.5 to 50 mg of cross-linked
(15 equiv) 50 mol % Man9-CWK18/PEG-VS-
CWK18 DNA co-condensates administered either
via the jugular vein (2.5 mg) or tail vein (50 mg)
established that neither the dosing location nor
DNA quantity signi®cantly altered Kupffer cell
targeting selectivity (not shown).
A 60-min tissue biodistribution pro®le for
cross-linked (6, 15, or 50 equiv) 50 mol % Man9-
CWK18/PEG-VS-CWK18 DNA co-condensates
demonstrated the in¯uence of cross-linking level
on DNA tissue biodistribution (Figure 3A±C).
Depending on cross-linking level, 5±10% of the
DNA targeted to lung, with 10±25% targeted to
spleen and only trace quantities (< 2%) detected
in other organs. At each cross-linking level, the
majority of the radioactivity was recovered in
liver (39±61%), which increased with increasing
cross-linking level, reaching 61% when using 50
equiv of glutaraldehyde.
The total radioactivity recovered from tissues
following a 60-min biodistribution was 62%
when cross-linked with 6 equiv of glutaraldehyde
(Figure 3A, open bar). This amount increased to
91% when using 15 equiv (Figure 3B, open bar) of
glutaraldehyde and nearly 100% when cross-link-
ing with 50 equiv of glutaraldehyde (Figure 3C,
open bar). The unaccounted radioactivity at lower
cross-linking levels was recovered in blood or
excreted into the urine as discussed in greater
detail later.
Analysis of the biodistribution over time
revealed a correlation between the level of glutar-
aldehyde cross-linking and the elimination rate of
DNA from liver (t1/2, Figure 4). With glutaralde-
hyde cross-linking of 6 equiv, the t1/2 was 4±5 h
for DNA formulations composed of either 50 mol
% AlkCWK18/PEG-VS-CWK18 (Figure 4A), Man9-
CWK18/PEG-VS-CWK18 (Figure 4D), or Man9-
CWK18/PEG-SS-CWK18 (Figure 4G). Increasing
the glutaraldehyde cross-linking to 15 equiv
increased the t1/2 to 6±11 h (Figures 4B, E and
H), for each formulation whereas cross-linking
with 50 equiv of glutaraldehyde produced a very
long t1/2 that ranged from 39 to 83 h for each
formulation (Figures 4C, E, and I).
Analysis of the early biodistribution pro®le re-
vealed that the liver-targeting ef®ciency reached
Figure 2. Cell-type speci®c targeting of cross-linked
DNA co-condensates. The ratio of [125I]DNA recovered
from hepatocytes and Kupffer cells following iv dosing
of different formulations is illustrated. The formula-
tions studied are (A) 125I-plasmid DNA; (B) cross-linked
(15 equiv) AlkCWK18/PEG-VS-CWK18 (50:50 mol %);
(C) cross-linked (15 equiv) PEG-VS-CWK18 (100 mol %);
(D) cross-linked (15 equiv) Man9-CWK18/PEG-VS-
CWK18 (2:98 mol %); (E) cross-linked (15 equiv)
Man9-CWK18/PEG-VS-CWK18 (10:90 mol %); (F)
cross-linked (15 equiv) Man9-CWK18/PEG-VS-CWK18
(50:50 mol %); (G) cross-linked (15 equiv) Man9-CWK18/
PEG-VS-CWK18 (75:25 mol %); (H) cross-linked
(15 equiv) Man9-CWK18/PEG-SS-CWK18 (50:50 mol
%); (I) cross-linked (15 equiv) Man9-CWK18/PEG-VS-
CWK18 (50:50 mol %) administered after 3.5 mg of
Man-BSA; (J) cross-linked (15 equiv) Man9-CWK18/
PEG-VS-CWK18 (50:50 mol %) administered after
3.5 mg of BSA; (K) cross-linked (50 equiv) Man9-
CWK18/PEG-VS-CWK18 (50:50 mol %). Each bar repre-
sents the mean and standard deviation of three
independent measurements.
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a maximum of 40±60% at 30 min, with 6 equiv
cross-linking (Figures 4A, D, and G, insets),
followed by a rapid decline to nearly zero at 24 h.
Increasing the cross-linking to 15 equiv also
produced a maximal liver-targeting ef®ciency of
40±60% at 30 min that declined more slowly as a
result of decreased metabolism (Figures 4B, E,
and H insets). Cross-linking with 50 equiv of
glutaraldehyde had the effect of decreasing
the initial liver-targeting ef®ciency at 5 min to
27±35%. This result was followed by glutaralde-
hyde accumulation in the liver over time to reach
40±60% at 60 min, which plateaued at a max-
imum of nearly 60±70% after 4 h and then
proceeded on a slow decline due to metabolism
(Figures 4C, E, and I, insets).
The lag time in the liver accumulation of
[125I]DNA co-condensates using 50 equiv of
glutaraldehyde cross-linking was assumed to be
the result of an increase in the circulatory half-life
(a t1/2). To investigate this hypothesis, the
pharmacokinetics of DNA co-condensates pre-
pared as either 50 mol % Man9-CWK18/PEG-VS-
CWK18 or AlkCWK18/PEG-VS-CWK18, stabilized
with either 6 or 50 equiv of glutaraldehyde, were
compared. Cross-linked (6 equiv) 50 mol % Man9-
CWK18/PEG-VS-CWK18 [
125I]DNA co-conden-
sates produced a short a t1/2, which ended
abruptly at 15 min and led to a steady-state level
Figure 3. Tissue biodistribution of [125I]DNA formu-
lations in mice. The 60-min tissue biodistribution of iv
dosed cross-linked (6, 15, and 50 equiv) Man9-CWK18/
PEG-VS-CWK18 (50 mol %) [
125I]DNA co-condensates
in mice are illustrated. Panels A, B, and C, illustrate the
targeting ef®ciency (% of dose) for formulations cross-
linked with 6, 15, and 50 equiv of glutaraldehyde
respectively. The open bar in each panel represent the
total recovery of radioactivity in the tissues. Each result
represents the mean and standard deviation of three
independent analysis.
Figure 4. Liver biodistribution pro®le for [125I]DNA
formulations in mice. The time course of liver targeting
and elimination of iv dosed [125I]DNA formulations in
mice are illustrated. Each panel illustrates the target-
ing ef®ciency (% of dose in liver) determined over 3 days
following a single iv dose. The insets in each panel
expand the early biodistribution during 0±2 or 0±6 h.
The calculated half-life (t1/2) of DNA in the liver is
indicated in each panel. Panel A, B, and C represent
50 mol % AlkCWK18/PEG-VS-CWK18 [
125I]DNA co-
condensates cross-linked with 6, 15 or 50 equiv of
glutaraldehyde, respectively. Panels D, E, and F
represent 50 mol % Man9-CWK18/PEG-VS-CWK18
[125I]DNA co-condensates cross-linked with 6, 15, or
50 equiv of glutaraldehyde, respectively. By compar-
ison, Panels G, H, and I represent 50 mol % Man9-
CWK18/PEG-SS-CWK18 [
125I]DNA co-condensates
cross-linked with 6, 15, or 50 equiv of glutaraldehyde,
respectively. Each result represents the mean and
standard deviation of three independent analysis.
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of radioactivity in the blood over time (Figure 5).
This result is consistent with metabolism in liver
and release of DNA fragments into the circula-
tion. Comparison of these results with the
pharmacokinetic pro®le for cross-linked (6 equiv)
50 mol % AlkCWK18/PEG-VS-CWK18 [
125I]DNA
co-condensates, which lack a targeting ligand,
established a slower a distribution phase followed
by a prolonged elimination phase, which is also
most likely the result of liver metabolism of DNA.




the in¯uence of mannose receptor-mediated
uptake of the former.
By comparison, the amount of radioactivity
(cpms) recovered in 10 mL of blood decreased
nearly 100-fold over 40 min following iv dosing of
cross-linked (50 equiv) 50 mol % Man9-CWK18/
PEG-VS-CWK18 [
125I]DNA co-condensates, result-
ing in only trace detection of radioactivity (< 1% of
dose) in blood after 60 min (Figure 5). The nearly
complete extraction of the DNA condensates
from the blood also appeared coincident in
time with the liver accumulation of radioactivity
(Figure 4F).
Alternatively, cross-linked (50 equiv) 50 mol %
AlkCWK18/PEG-VS-CWK18 [
125I]DNA co-conden-
sates had much longer a and b half-lives,
apparently because of non-recognition by the
mannose receptor and the delay in metabolism.
The amount of radioactivity (cpms) recovered in
blood slowly declined to 20% of maximum over
3 h, which occurred coincidentally with the accu-
mulation of radioactivity in the liver (Figure 4C).
The amount of radioactivity (cpms) in blood is
likely intact [125I]-DNA because the liver metabo-
lism of this formulation is much slower. However,
this explanation is unproven because it was not
possible to uncondense cross-linked DNA conden-
sates recovered from blood and analyze the
DNA structure by gel electrophoresis. Nonethe-
less, ®tting of the pharmacokinetic data for
50 equiv of cross-linked AlkCWK18/PEG-VS-
CWK18 [
125I]DNA co-condensates to a two-com-
partment model28 produced a mean residence
time of 4 h, establishing an apparent prolonged
circulation for highly stabilized DNA condensates
lacking a targeting ligand.
The gene expression mediated by a single iv
bolus dose of 50 mol % Man9-CWK18/PEG-CWK18
(VS or SS) DNA co-condensates cross-linked with
either 6, 15, or 50 equiv of glutaraldehyde was
evaluated in mice. When cross-linking with 6 equiv
of glutaraldehyde, the hAAT expression pro®le
over 10 days appeared coincident between for-
mulations possessing either PEG-VS-CWK18 or
PEG-SS-CWK18 (Figures 6A versus B). For each
formulation, the days 0.5±5 expression of 1±
10 ng/mL was followed by a spike of expression of
15±20 ng/mL occurring at day 6. Comparison of
these results with the hAAT expression pro®les
mediated by formulations cross-linking with
15 equiv of glutaraldehyde established a nearly
two-fold higher level of expression at each day
across the 10-day pro®le, with a dampening of the
peak expression at day 6 (Figures 6C and D).
A further increase in the glutaraldehyde cross-
linking to 50 equiv resulted in a decrease in
the overall level of hAAT expression to 3±10 ng/
mL, with exception of the 0.5 day time point,
which showed negligible expression. These re-
sults are contrasted by the gene expression
mediated by cross-linked (15 equiv) 50 mol %
AlkCWK18/PEG-VS-CWK18 DNA co-condensates
(Figure 6F), which produce only background
levels (1±3 ng/ML) of hAAT despite their biodis-
tribution and retention in the liver with a t1/2 of
11.6 h (Figure 4B).
DISCUSSION
The mannose receptor found on Kupffer cells
along with the ASGP-R on hepatocytes represent
Figure 5. Pharmacokinetic analysis of cross-linked
DNA co-condensates. The pharmacokinetic analysis of
50 mol % Man9-CWK18/PEG-VS-CWK18 [
125I]DNA co-
condensates cross-linked with 6 (~) and 50 (*) equiv of
glutaraldehydeare is compared with that of 50 mol %
AlkCWK18/PEG-VS-CWK18 [125I]DNA co-condensates
cross-linked with 6 (^) and 50 (&) equiv of glutar-
aldehyde. Each analysis represents the mean and
standard deviation of three determinations.
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ideal proving grounds to test hypotheses related
to nonviral gene delivery systems.29 An iv dosed
DNA formulation can be directed to either cell
type depending on the nature of the targeting
ligand (mannose versus galactose) by simulta-
neously blocking nonspeci®c binding and up-
take.11,15,17,30,31 In addition to differences in
monosaccharide speci®city, the topography of
the two receptors further differentiate their
speci®city for binding multivalent ligands.27 The
mannose receptor is unique among C-type lectins
in its preferred binding of clustered glycosides
possessing mannose residues spaced by> 50 AÊ ,
such as would be found on a foreign organism.27
This binding preference is in contrast to that of
the ASGP-R, which is composed of a cluster of
three carbohydrate recognition domains that
bind simultaneously to three galactose resid-
ues on a single triantennary N-glycan spaced by
20 AÊ .32
The use of a LMW high-mannose glycopeptide
along with a PEG-peptide led to the formulation of
DNA co-condensates that shield the DNA surface
charge without masking the ligand recognition.
The underlying carbohydrate scaffold of the Man9
N-glycan apparently extends the terminal man-
nose residues 20 AÊ from the surface33 of the
DNA condensate so that the ligand is no longer
sterically blocked by 5 kDa PEG chains and can be
recognized by the mannose receptor.
In contrast to the ASGP-R, which only required
2 mol % triantennary glycopeptide to mediate
maximal (80%) targeting selectivity to hepato-
cytes,17 optimal Kupffer cell targeting required
50 mol % Man9-CWK18. This result is under-
standable considering the differences in the
binding site topography and ligand spacing
requirements of the two receptors.27,32 This result
differs from the ®nding of Ferkol et al. who re-
ported mannose receptor targeting of DNA con-
densates to Kupffer cells or lung macrophages
using 1% mannosylated HMW polylysine,
although the cell-type targeting selectivity was
not measured.9,10 Alternatively, the data pre-
sented here agrees more closely with the results
Nishikawa et al. who found that a mannosylated
polylysine (29 kDa) possessing 11 mannose resid-
ues per polylysine chain was able to mediate 80%
targeting to Kupffer cells,11 even without the use
of PEG to block nonspeci®c targeting.
An objective of the present study was to
examine the consequence of increasing the glu-
taraldehyde cross-linking on DNA co-conden-
sates. Varying this parameter had little effect on
surface charge but led to a progressive increase in
the particle size (Table 1, E, H±J) resulting from a
second (5±15%) larger (1 mm) population of DNA
co-condensates. These was no difference in the
Kupffer cell targeting selectivity for DNA con-
densates cross-linked with either 15 or 50 equiv of
glutaraldehyde (Figure 2, F versus J), even though
the percentage of dose targeted to the spleen
increased to 30% at 50 equiv cross-linking
(Figure 3C). These ®ndings differ from those of
Nishikawa et al. who reported< 10% lung or
spleen targeting for mannosylated polylysine
DNA condensates despite a particle size of
220 nm and a positive zeta potential.11 Likewise,
Ferkol et al. reported that small (< 20 nm)
mannosylated polylysine DNA condensates pre-
ferentially targeted to spleen versus liver but
Figure 6. In vivo gene expression of cross-linked
DNA co-condensates. The 10-day transient gene
expression pro®le of hAAT in mice is compared
following a single 50-mg tail vein dose of a DNA
formulation. Panels A and B compare the result of
dosing of equiv cross-linked 50 mol % Man9-CWK18/
PEG-VS-CWK18 DNA co-condensates (A) with an
otherwise identical formulation (B) that substitutes
PEG-SS-CWK18 for PEG-VS-CWK18 The results in
panels C and D also compare the gene expression
mediated by 50 mol % Man9-CWK18/PEG-CWK18 DNA
co-condensates composed of PEG-VS-CWK18 (C) and
PEG-SS-CWK18 (D) but cross-linked with 15 equiv of
glutaraldehyde. Panel E illustrates the gene expression
mediated by 50 equiv cross-linked 50:50 mol % Man9-
CWK18/PEG-VS-CWK18 DNA co-codensates and panel
F illustrates a control when dosing 15 equiv cross-
linked 50:50 mol % AlkCWK18/PEG-VS-CWK18 DNA
co-condensates. Each data point represents the mean
and standard error for 3 mice. Comparison of the
results of panels C and D with those in F establish a
statistical signi®cance ( p< 0.001) at each day.
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were unable to demonstrate that this preference
was due to mannose receptor-mediated gene
delivery by competitive inhibition.9,10 Results
from the present study suggest that spleen
targeting is most likely related to the particle
size and not the result of speci®c binding to
the mannose receptor on spleen macrophages
because cross-linked (50 equiv) AlkCWK18/PEG-
CWK18 DNA co-condensates also distributed to
spleen to a comparable degree.
Previously we found a difference in the in vitro
gene transfer ef®ciency of PEG-SS-CWK18 and
PEG-VS-CWK18 DNA condensates resulting from
reduction of the disul®de bond of the former
during a 5-h transfection.26 In the present study,
a similar comparison of the in vivo performance of
both PEG-peptides established no difference in
the cell-type speci®c targeting, metabolic half-life,
or transient gene expression pro®le. The disul®de
bond in PEG-SS-CWK18 is apparently resistant to
reduction during circulation because the prema-
ture loss of PEG would most certainly perturb the
ratio of hepatocyte and Kupffer cell targeting. It is
clear, however, that PEG is an essential compo-
nent of a gene delivery carrier to block nonspeci®c
protein binding to electropositive DNA conden-
sates resulting in lung targeting.15,30,31,34
The ability to control the metabolic half-life of
DNA co-condensates by changing the glutaralde-
hyde cross-linking level is a unique feature of this
DNA formulation. The mechanism by which
glutaraldehyde cross-linking delays DNA meta-
bolism is most likely related to either caging of the
DNA to protect it from DNase35 or chemical
masking of the peptide backbone of PEG-CWK18
and Man9-CWK18 from proteases by derivati-
zation of the lysine side chains.23 The results
presented in Figure 4 indicate that increasing the
glutaraldehyde cross-linking from 6 to 15 equiv
nearly doubles the t1/2 from 3.7 to 6 h and
similarly in¯uences the level of transient gene
expression (Figures 6A, versus 6C). The produc-
tion of gene product in Kupffer cells appears to be
strictly dependent on the presence of a targeting
ligand because a control formulation lacking
the high-mannose N-glycan distributed non-
speci®cally between hepatocytes and Kupffer
cells (Figure 2B) and possessed a t1/2 of 11.6 h
(Figure 4B) but failed to mediate gene expression
(Figure 6F).
At very high cross-linking levels (50 equiv), the
half-life was extended to 2±3 days but the level of
gene expression each day was lower (Figure 6E).
This result is similar to that observed when
studying glutaraldehyde cross-linked DNA con-
densates in vitro17 and might be expected if cross-
linked DNA condensates only release plasmid
DNA slowly inside the target cell. The ability to
control the intracellular release rate of DNA may
result in the ability to control the duration of gene
expression.
An important and unexpected consequence of
glutaraldehyde cross-linking was its in¯uence on
the apparent pharmacokinetic pro®le of DNA
formulations. The long pharmacokinetic half-life
of cross-linked (50 equiv) 50 mol % AlkCWK18/
PEG-VS-CWK18 DNA co-condensates (Figure 5)
in conjunction with the delayed liver accumula-
tion over 3 h (Figure 4C, inset) suggest stabilized
DNA co-condensate possessing at least 50 mol %
PEG remain in the circulation and are only slowly
captured by the liver. This result has implications
for the design of DNA condensates that target to
peripheral tissues.30
In conclusion, we examined the function of a
LMW peptide carrier molecules to facilitate
speci®c targeting of DNA to Kupffer cells in vivo
and protect the targeted DNA from premature
metabolism. The results indicate that increasing
DNA condensate cross-linking decreases DNA
metabolism and has an overall effect of increasing
the level of gene expression. At very high cross-
linking levels, the transient gene expression is
suppressed, but this could also lead to an increase
in the duration of gene expression. This hypo-
thesis must be systematically explored in a future
study.
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